 |
canakinumab |
|---|---|
| Trade Name | Ilaris |
| Orphan Indication | Pediatric (age 16 and under) juvenile rheumatoid arthritis |
| USA Market Approval | USA |
| USA Designation Date | 2008-09-30 00:00:00 |
| Sponsor | Novartis Pharmaceuticals Corporation;One Health Plaza, Bldg 135-566G;East Hanover, New Jersey, 07936 |
